[PDF][PDF] Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia
FY Mortuza, M Papaioannou, IM Moreira… - Journal of Clinical …, 2002 - Citeseer
FY Mortuza, M Papaioannou, IM Moreira, LA Coyle, P Gameiro, D Gandini, HG Prentice…
Journal of Clinical Oncology, 2002•CiteseerResults: Fisher's exact test established a statistically significant concordance between MRD
results and clinical outcome at all times. Disease-free survival (DFS) rates for MRD-positive
and-negative patients and logrank testing established that MRD positivity was associated
with increased relapse rates at all times (P<. 05) but was most significant at 3 to 5 months
after induction and beyond. MRD status after allogeneic BMT rather than before was found
to be an important predictor of outcome in 19 adult patients with ALL tested. In patients …
results and clinical outcome at all times. Disease-free survival (DFS) rates for MRD-positive
and-negative patients and logrank testing established that MRD positivity was associated
with increased relapse rates at all times (P<. 05) but was most significant at 3 to 5 months
after induction and beyond. MRD status after allogeneic BMT rather than before was found
to be an important predictor of outcome in 19 adult patients with ALL tested. In patients …
Results: Fisher’s exact test established a statistically significant concordance between MRD results and clinical outcome at all times. Disease-free survival (DFS) rates for MRD-positive and-negative patients and logrank testing established that MRD positivity was associated with increased relapse rates at all times (P<. 05) but was most significant at 3 to 5 months after induction and beyond. MRD status after allogeneic BMT rather than before was found to be an important predictor of outcome in 19 adult patients with ALL tested. In patients receiving autologous BMT (n 16), the MRD status before BMT was more significant (P. 005).
Conclusion: The association of MRD test results and
Citeseer